Utility of Hepatitis C Viral Load Monitoring on Direct-Acting Antiviral Therapy
Open Access
- 2 March 2015
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 60 (12) , 1743-1751
Abstract
Background. Hepatitis C virus (HCV) RNA loads serve as predictors of treatment response during interferon-based therapy. We evaluated the predictive ability of HCV RNA levels at end of treatment (EOT) for sustained virologic response (SVR12) during interferon-sparing direct-acting antiviral therapies. Methods. HCV genotype 1–infected, treatment-naive patients were treated with sofosbuvir and ribavirin for 24 weeks (n = 55), sofosbuvir and ledipasvir for 12 weeks (n = 20), sofosbuvir, ledipasvir, and GS-9669 for 6 weeks (n = 20), or sofosbuvir, ledipasvir, and GS-9451 for 6 weeks (n = 19). Measurements of HCV RNA were performed using the Roche COBAS TaqMan HCV test and the Abbott RealTime HCV assay. Positive predictive value (PPV) and negative predictive value (NPV) of HCV RNA less than the lower limit of quantification (12 were calculated. Results. All 55 patients treated with sofosbuvir and ribavirin had HCV RNA 12 (PPV, 69%). Among patients treated with sofosbuvir and ledipasvir with or without GS-9669 or GS-9451, 100% (59/59) had HCV RNA 12 (NPV, 0%). Quantifiable HCV RNA (range, 15–57 IU/mL) was measured 2 weeks posttreatment in 4 individuals, and 4 weeks posttreatment in 1 patient (14 IU/mL). Conclusions. Contrary to past experience with interferon-containing treatments, low levels of quantifiable HCV RNA at EOT do not preclude treatment success.Keywords
This publication has 24 references indexed in Scilit:
- Sofosbuvir for the treatment of hepatitis C virusExpert Opinion on Pharmacotherapy, 2013
- Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment CharacteristicsJAMA, 2013
- 1 ALTERED HCV SPECIFIC T CELL IMMUNITY VERY EARLY IN INTERFERON FREE HCV DAA THERAPYJournal of Hepatology, 2013
- Closing in on the Target: Sustained Virologic Response in Hepatitis C Virus Genotype 1 Infection Response-Guided TherapyClinical Infectious Diseases, 2013
- Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agentsHepatology, 2012
- Performance of the Abbott RealTime and Roche Cobas TaqMan Hepatitis C Virus (HCV) Assays for Quantification of HCV GenotypesJournal of Clinical Microbiology, 2012
- Boceprevir for Untreated Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2011
- Interpretation of Real-Time PCR Results for Hepatitis C Virus RNA When Viral Load Is Below Quantification LimitsJournal of Clinical Microbiology, 2011
- Peginterferon Alfa-2a and Ribavirin for 24 Weeks in Hepatitis C Type 1 and 4 Patients With Rapid Virological ResponseGastroenterology, 2008
- The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwideJournal of Hepatology, 2006